Análise da expressão de genes relacionados à baixa densidade mineral óssea : avaliação prognóstica e de conduta terapêutica para osteoporose

• Autor(a) principal: Souza, Leticia Soncini de
• Data de Publicação: 2013
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
• Texto Completo: http://repositorio.ufes.br/handle/10/1885
• topic: Estrogen receptor alpha; Osteoporosis; Receptor alfa de estrogênio; Apolipoproteína E; Biotecnologia; Polimorfismo (Genética); Menopausa; Osteoporose; 61

Since that assuming the knowledge of the regulatory mechanisms of bone formation and resorption is crucial in the search for alternative therapies in diseases such as osteoporosis, molecular biology emerges as interesting tool and essential to achieving this goal. Among these genetic markers, gene polymorphisms associated with estrogen receptor alpha (ERα) and the gene Apolipoprotein " E" (ApoE) have received increased attention in recent years. The aim of this study was to analyze the expression of polymorphisms PvuII (CT nt -397) and XbaI (GA nt -351) gene present in REα and polymorphisms in the gene ApoE (HhaI - ε2 , ε3 and ε4) in populations of postmenopausal women, associating these gene alterations, and their clinical and biochemical profiles with osteoporosis. After analyzing the results obtained, the PvuII SNP in the gene of ERα is related to low BMD, and this effect is most noticeable in women with advanced age. The P allele, however, correlates strongly with high BMD (p < 0.05) in the whole population studied and reproduced when analyzing the population aged over 65 years, suggesting a protective role in the loss of bone mineral. In XbaII SNP, of same gene, a significant association of allele x at concentrations of triglycerides and total lipids and dependence on patient age and Body Mass Index (BMI) was observed. On the other hand, for SNP HhaI, ApoE gene, the E2 allele may be associated as a risk factor for low BMD, and E3 allele may be associated as a protective factor in relation to BMD. These results contribute to a better understanding of the expression of genes related to osteoporosis and can provide information for better prognostic determination of the disease as well as rationalization of therapeutic conduct to be chosen, providing a better quality of life for postmenopausal patients.